Poorly differentiated carcinoma of thyroid

Khetrapal, Shaan; Rana, Safia; Jetley, Sujata; Jairajpuri, Zeeba S

doi:10.4103/0973-1482.187239

Cited by 6 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the majority of studies in our review, the extent of the poorly differentiated area was not reported, and a PDTC definition was decided to address this component. A large number of patients with PDTC reviewed herein presented with locally advanced disease (T3 or T4, extrathyroidal extension, and nodal involvement) [ 40 , 44 , 46 , 47 , 49 , 50 , 51 , 54 , 55 , 57 , 58 , 60 , 61 , 62 , 64 , 67 , 68 , 69 , 70 , 71 , 73 , 74 , 75 , 76 , 77 , 78 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 90 , 91 , 92 , 94 , 97 , 98 , 99 , 100 , 101 , 102 , 107 , 108 , 109 , 111 , 112 , 113 , 114 , 115 , 116 ,…”

Section: Discussionmentioning

confidence: 99%

“…In the majority of studies in our review, the extent of the poorly differentiated area was not reported, and a PDTC definition was decided to address this component. A large number of patients with PDTC reviewed herein presented with locally advanced disease (T3 or T4, extrathyroidal extension, and nodal involvement) [40,44,46,47,[49][50][51]54,55,57,58,[60][61][62]64,[67][68][69][70][71][73][74][75][76][77][78][80][81][82][83][84][85][86][87][88][90][91][92]94,[97][98][99][100][101][102][107][108][109]…”

Section: Histologymentioning

confidence: 99%

See 1 more Smart Citation

The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review

Violetis,

Konstantakou,

Spyroglou

et al. 2024

JPM

View full text Add to dashboard Cite

Background: Poorly differentiated thyroid carcinoma (PDTC) has an intermediate prognosis between indolent well-differentiated thyroid carcinoma (TC) and anaplastic carcinoma. Herein, we present a case report with a PDTC component, along with a systematic review of the literature. Case Report: We report a case of a 45-year-old man diagnosed with a PDTC component, along with hobnail and tall-cell variant features positive for BRAFV600E mutation, after a total thyroidectomy and neck dissection. Radioactive iodine (RAI)-131 therapy was applied, but an early recurrence led to complementary surgeries. The anti-Tg rise, the presence of new lymph nodes, and the negative whole-bodyradioiodine scan were suggestive of a radioiodine-resistant tumor. Lenvatinib, sorafenib, dabrafenib/trametinib, cabozantinib and radiotherapy were all administered, controlling the tumor for a period of time before the patient ultimately died post-COVID infection. Systematic Review: We searched PubMed, Scopus, and WebofScience to identify studies reporting clinicopathological characteristics, molecular marker expression, and management of non-anaplastic TC with any proportion of PDTC in adult patients. Of the 2007 records retrieved, 82were included in our review (PROSPERO-ID545847). Conclusions: Our case, together with the systematic review, imply that a combination of molecular-targetedtreatments may be safe and effective in patients with RAI-resistantBRAF-mutated advanced PDTC when surgery has failed to control tumor progression.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In the majority of studies in our review, the extent of the poorly differentiated area was not reported, and a PDTC definition was decided to address this component. A large number of patients with PDTC reviewed herein presented with locally advanced disease (T3 or T4, extrathyroidal extension, and nodal involvement) [40,44,46,47,[49][50][51]54,55,57,58,[60][61][62]64,[67][68][69][70][71][73][74][75][76][77][78][80][81][82][83][84][85][86][87][88][90][91][92]94,[97][98][99][100][101][102][107][108][109]…”

Section: Histologymentioning

confidence: 99%

The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review

Violetis,

Konstantakou,

Spyroglou

et al. 2024

JPM

View full text Add to dashboard Cite

show abstract

“…PDTCs represents about 0.3% to 6.7% of all thyroid malignancies and display an aggressive clinical behavior, with a poor prognosis [8]. Anaplastic thyroid cancer (ATC) is the most aggressive and lethal form of UDTCs.…”

Section: Introductionmentioning

confidence: 99%

MiR-19a Overexpression in FTC-133 Cell Line Induces a More De-Differentiated and Aggressive Phenotype

Calabrese¹,

Dolcimascolo²,

Torrisi³

et al. 2018

IJMS

View full text Add to dashboard Cite

In recent years, microRNAs (miRNAs) have received increasing attention for their important role in tumor initiation and progression. MiRNAs are a class of endogenous small non-coding RNAs that negatively regulate the expression of several oncogenes or tumor suppressor genes. MiR-19a, a component of the oncogenic miR-17-92 cluster, has been reported to be highly expressed only in anaplastic thyroid cancer, the most undifferentiated, aggressive and lethal form of thyroid neoplasia. In this work, we evaluated the putative contribution of miR-19a in de-differentiation and aggressiveness of thyroid tumors. To this aim, we induced miR-19a expression in the well-differentiated follicular thyroid cancer cell line and evaluated proliferation, apoptosis and gene expression profile of cancer cells. Our results showed that miR-19a overexpression stimulates cell proliferation and alters the expression profile of genes related to thyroid cell differentiation and aggressiveness. These findings not only suggest that miR-19a has a possible involvement in de-differentiation and malignancy, but also that it could represent an important prognostic indicator and a good therapeutic target for the most aggressive thyroid cancer.

show abstract

Cytologic features of aggressive variants of follicular‐derived thyroid carcinoma

Rossi

Faquin

Pantanowitz

2019

Cancer Cytopathology

View full text Add to dashboard Cite

Certain carcinomas of the thyroid gland behave aggressively resulting in increased patient morbidity and poor patient prognosis. The diagnosis of these aggressive thyroid cancer subtypes is sometimes challenging and subject to increased interobserver variability. This review deals with the cytological features of such tumors including aggressive variants of papillary thyroid carcinoma, poorly differentiated thyroid carcinoma, and anaplastic thyroid carcinoma. These malignancies fall into 2 groups based on their cytomorphology: those that exhibit distinct microscopic features (eg, nuclear findings typical of classical papillary thyroid carcinoma or marked anaplasia) and those that present with more subtle cytologic features (eg, nuclear pseudostratification, “soap bubble” nuclei, supranuclear or subnuclear cytoplasmic vacuoles, rosette‐like structures, hobnail cells). We review the literature regarding these aggressive thyroid cancers and highlight important phenotypic characteristics that can be useful for their diagnosis based on fine needle aspiration.

show abstract

Poorly differentiated carcinoma of thyroid

Cited by 6 publications

References 8 publications

The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review

The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review

MiR-19a Overexpression in FTC-133 Cell Line Induces a More De-Differentiated and Aggressive Phenotype

Cytologic features of aggressive variants of follicular‐derived thyroid carcinoma

Contact Info

Product

Resources

About